Fluvastatin titrate-to-goal clinical practice study

American Journal of Therapeutics

Volumn 5, Issue 5, 1998, Pages 281-285

  Weiss, Robert J ^a  

^a Androscoggin Cardiology Associates   (United States)

Author keywords

Fluvastatin; Hypercholesterolemia

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031710469     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199809000-00002     Document Type: Article

References (7)

1. The Scandinavian Simvastatin Survival Group: Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
3. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
4. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
5. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
6. Byington RP, Jukena JW, Salonen JT, et al: Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92:2419-2425.
7. Herd JA, West MS, Ballantyne C, et al: Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol 1994;73(Suppl):42D-49D.